[Federal Register Volume 84, Number 242 (Tuesday, December 17, 2019)]
[Notices]
[Page 68939]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-27102]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; PHASE I: NIDA Avant-Garde Award Program for HIV/AIDS 
and Drug Use Research (DP1) (Mail) and Phase II: NIDA Avant Garde 
Award Program for HIV/AIDs and Drug Use Research (DP1) (Interview).
    Date: December 18, 2019.
    Time: 8:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Courtyard by Marriott, 5520 Wisconsin Avenue, Chevy 
Chase, MD 20815.
    Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer, 
Office of Extramural Affairs, National Institute on Drug Abuse, 
National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 
4238, MSC 9550, Bethesda, MD 20892, 301-402-6020, 
[email protected].

    This notice is being published less than 15 days prior to the 
meeting due to the urgent need to meet timing limitations imposed by 
the intramural research review cycle.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Mechanism for Time-Sensitive Drug Abuse Research 
(R21 Clinical Trial Optional).
    Date: December 20, 2019.
    Time: 1:00 p.m. to 3:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center 
Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852 
(Telephone Conference Call).
    Contact Person: Susan O. McGuire, Ph.D., Scientific Review 
Officer, Office of Extramural Affairs, National Institute on Drug 
Abuse, National Institutes of Health, DHHS, 6001 Executive Blvd., 
Room 4245, Rockville, MD 20852, 301-435-1426, 
[email protected].

    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)

    Dated: December 11, 2019.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-27102 Filed 12-16-19; 8:45 am]
BILLING CODE 4140-01-P